Physician profile
Bruce R Wall
NPI 1861446130
$5,455.86
in general payments reported to CMS, 2019-2025
33 companies · $561 in 2025
The $561 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,254 · 2020: $1,191 · 2021: $869 · 2022: $412 · 2023: $605 · 2024: $563 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,718 · Education: $11.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,718.28 |
| Education | $11.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $830.34 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $652.26 | 2021-2024 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $616.81 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $467.13 | 2019-2025 | Jynarque |
| Fresenius USA Marketing, INC. | $285.81 | 2019-2025 | Velphoro, Velphoro |
| Amgen INC. | $236.71 | 2019-2025 | Tavneos, Krystexxa |
| Glaxosmithkline, LLC. | $232.37 | 2019-2023 | Benlysta |
| Vifor Pharma, INC. | $202.60 | 2019-2023 | Veltassa |
| Alexion Pharmaceuticals, INC. | $198.73 | 2019-2024 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $183.56 | 2020-2023 | Acthar |
| Genentech USA, INC. | $158.62 | 2019-2020 | |
| Calliditas Therapeutics US INC. | $151.04 | 2023-2025 | Tarpeyo |
| Akebia Therapeutics INC | $126.54 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.19 | 2021-2024 | |
| Novo Nordisk INC | $114.04 | 2021-2025 | Ozempic, Rybelsus |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $90.56 | 2023-2025 | |
| Horizon Therapeutics Plc | $86.19 | 2022-2023 | Krystexxa |
| Alnylam Pharmaceuticals INC. | $73.97 | 2019-2024 | Givlaari |
| Mallinckrodt Enterprises LLC | $70.87 | 2019 | |
| Cormedix INC. | $70.27 | 2024 | Defencath |
| Opko Pharmaceuticals, LLC | $62.55 | 2019-2025 | Rayaldee |
| Recor Medical INC | $60.61 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Ardelyx, INC. | $60.02 | 2024-2025 | Ibsrela |
| Ani Pharmaceuticals, INC. | $50.44 | 2022-2024 | Purified Cortrophin Gel |
| Amarin Pharma, INC. | $47.73 | 2021 | |
| Travere Therapeutics, INC. | $45.90 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.69 | 2024-2025 | Jardiance |
| Pfizer INC. | $35.66 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $19.97 | 2024 | Recarbrio, Dificid, Zerbaxa |
| Kyowa Kirin, INC. | $19.56 | 2025 | |
| Janssen Pharmaceuticals, INC | $17.47 | 2019 | |
| Renalytix Ai, INC. | $15.98 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Portola Pharmaceuticals, LLC | $14.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Wall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.